Submission for OMB Review; Generic Clearance for the Comprehensive Child Welfare Information System (CCWIS) Review and Technical Assistance Process (New Collection)

Citation85 FR 86936
Record Number2020-28925
Published date31 December 2020
SectionNotices
CourtChildren And Families Administration
86936
Federal Register / Vol. 85, No. 251 / Thursday, December 31, 2020 / Notices
Services as the Privacy Act permits,
including in accordance with the
routine uses published for this system
in the Federal Register, and as
authorized by law. Such lawful
purposes may include but are not
limited to sharing identifiable
information with state and local public
health departments, and other
cooperating authorities. CDC and
cooperating authorities will retain, use,
delete, or otherwise destroy the
designated information in accordance
with federal law and the System of
Records Notice (SORN) set forth above.
You may contact the system manager at
dgmqpolicyoffice@cdc.gov; Division of
Global Migration and Quarantine,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS
H16–4, Atlanta, GA 30329, if you have
questions about CDC’s use of your data.
Authority
The authority for these orders is
Sections 361 and 365 of the Public
Health Service Act (42 U.S.C. 264) and
42 CFR 71.20 & 71.31(b).
Nina B. Witkofsky,
Acting Chief of Staff, Centers for Disease
Control and Prevention.
[FR Doc. 2020–28981 Filed 12–28–20; 4:15 pm]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Submission for OMB Review; Generic
Clearance for the Comprehensive
Child Welfare Information System
(CCWIS) Review and Technical
Assistance Process (New Collection)
AGENCY
: Children’s Bureau,
Administration for Children and
Families, HHS.
ACTION
: Request for public comment.
SUMMARY
: The Children’s Bureau (CB),
Administration for Children and
Families (ACF), U.S. Department of
Health and Human Services (HHS), is
proposing to establish a generic
clearance to collect information to
assess regulatory requirements of title
IV–E agencies’ Comprehensive Child
Welfare Information System (CCWIS)
and ensure that the CCWIS is utilized
for purposes consistent with the
efficient, economical, and effective
administration of the title IV–B and IV–
E plans. The information collected is
intended to be used for review and
technical assistance processes.
DATES
: Comments due within 30 days of
publication. OMB must make a decision
about the collection of information
between 30 and 60 days after
publication of this document in the
Federal Register. Therefore, a comment
is best assured of having its full effect
if OMB receives it within 30 days of
publication.
ADDRESSES
: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
SUPPLEMENTARY INFORMATION
:
Description: This initial request is to
establish an overarching generic for
CCWIS Review and Technical
Assistance (TA) information collections
and includes six initial TA tools for title
IV–E agencies to self-assess their
conformity to CCWIS project and design
requirements at 45 CFR 1355.52–3. The
initial six TA tools include intake,
investigation, case management,
adoption, foster care and service
provider management, and
administration.
In the future, ACF will submit under
this generic clearance mechanism
additional TA tools for title IV–E
agencies to self-assess design, data
quality, usability, reporting, data
exchanges, external systems, eligibility,
finance, Child Welfare Contributing
Agencies, and other tools, as needed, to
assess new child welfare programs and
modern system architecture.
The CCWIS requirements at 45 CFR
1355.55 require the review, assessment,
and inspection of the planning, design,
development, installation, operation,
and maintenance of each CCWIS project
on a continuing basis. The Advance
Planning Document regulations at 45
CFR 95.621 require periodic reviews of
state and local agency methods and
practices to insure that information
systems, including CCWIS, are utilized
for purposes consistent with proper and
efficient administration.
Respondents: Title IV–E agencies
under the Social Security Act.
A
NNUAL
B
URDEN
E
STIMATES
Instrument Total
number of
respondents
Total
number of
responses per
respondent
Average
burden
hours per
response
Total burden
hours
CCWIS Self-Assessment—Intake .................................................................... 55 1 10 550
CCWIS Self-Assessment—Investigation ......................................................... 55 1 10 550
CCWIS Self-Assessment—Case Management ............................................... 55 1 10 550
CCWIS Self-Assessment—Adoption ............................................................... 55 1 10 550
CCWIS Self-Assessment—Foster Care and Service Provider Management 55 1 10 550
CCWIS Self-Assessment—Administration ....................................................... 55 1 10 550
Future Tools to be Developed ......................................................................... 55 10 12 6,600
VerDate Sep<11>2014 19:28 Dec 30, 2020 Jkt 253001 PO 00000 Frm 00036 Fmt 4703 Sfmt 9990 E:\FR\FM\31DEN1.SGM 31DEN1
khammond on DSKJM1Z7X2PROD with NOTICES
86937
Federal Register / Vol. 85, No. 251 / Thursday, December 31, 2020 / Notices
Estimated Total Annual Burden
Hours: 9,900.
Authority: 5 U.S.C. 301; 42 U.S.C. 470, 620
et seq., 622(b), 629b(a), 652(b), 654A, 670 et
seq., 671(a), 1302, and 1396a(a).
Mary B. Jones,
ACF/OPRE Certifying Officer.
[FR Doc. 2020–28925 Filed 12–30–20; 8:45 am]
BILLING CODE 4184–25–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2016–N–0124 (Formerly
Docket No. FDA–1975–N–0012)]
Consumer Antiseptic Rub Final Rule;
Finding of Ineligibility for Inclusion in
Final Monograph Questions and
Answers; Guidance for Industry; Small
Entity Compliance Guide; Availability
AGENCY
: Food and Drug Administration,
HHS.
ACTION
: Notice of availability.
SUMMARY
: The Food and Drug
Administration (FDA or Agency) is
announcing the availability of a final
guidance for industry entitled
‘‘Consumer Antiseptic Rub Final Rule
Questions and Answers.’’ We are
issuing this guidance in accordance
with the Small Business Regulatory
Enforcement Fairness Act to help small
businesses understand and comply with
the Consumer Antiseptic Rub Final
Rule; Finding of Ineligibility for
Inclusion in Final Monograph
(Consumer Antiseptic Rub FR). In the
Consumer Antiseptic Rub FR, FDA
established that 28 active ingredients
used in nonprescription (also known as
over-the-counter (OTC)) consumer
antiseptic products intended for use
without water (consumer antiseptic
rubs) are not eligible for evaluation
under FDA’s OTC Drug Review, which
was used to evaluate the safety and
effectiveness of OTC drug products
marketed in the United States on or
before May 1972. The Consumer
Antiseptic Rub FR also established that
three active ingredients used in
consumer antiseptic rubs are eligible for
evaluation under the OTC Drug Review
and granted requests to temporarily
defer further rulemaking on these three
eligible ingredients to allow for the
development and submission of new
safety and effectiveness data.
DATES
: The announcement of the
guidance is published in the Federal
Register on December 31, 2020.
ADDRESSES
: You may submit either
electronic or written comments on
Agency guidances at any time as
follows:
Electronic Submissions
Submit electronic comments in the
following way:
Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
Mail/Hand delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2016–N–0124 for ‘‘Consumer Antiseptic
Rub Final Rule Questions and
Answers.’’ Received comments will be
placed in the docket and, except for
those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday, 240–402–7500.
Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://
www.govinfo.gov/content/pkg/FR-2015-
09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
You may submit comments on any
guidance at any time (see 21 CFR
10.115(g)(5)).
Submit written requests for single
copies of this guidance to the Division
of Drug Information, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10001 New
Hampshire Ave., Hillandale Building,
4th Floor, Silver Spring, MD 20993–
0002. Send one self-addressed adhesive
label to assist that office in processing
your requests. See the
SUPPLEMENTARY
INFORMATION
section for electronic
access to the guidance document.
FOR FURTHER INFORMATION CONTACT
:
Anita Kumar, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, Rm. 5445,
Silver Spring, MD 20993–0002, 301–
796–1032.
SUPPLEMENTARY INFORMATION
:
I. Background
FDA is announcing the availability of
a guidance for industry entitled
‘‘Consumer Antiseptic Rub Final Rule
VerDate Sep<11>2014 19:28 Dec 30, 2020 Jkt 253001 PO 00000 Frm 00037 Fmt 4703 Sfmt 4703 E:\FR\FM\31DEN1.SGM 31DEN1
khammond on DSKJM1Z7X2PROD with NOTICES

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT